Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome

Completed · Phase 2 · Has a placebo group

Conditions studied: Long COVID, Post-COVID Syndrome, Post COVID-19 Condition

In brief

REGENECYTE (HPC, Cord Blood, hUCB) for treatment in patients with post-COVID.

Key facts

Study ID

NCT05682560

Run by

StemCyte, Inc.

People needed

30

Starts

2023-05-04

Expected to finish

2025-02-27

Last updated by the study team

2025-03-24

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 1. Male or female aged ≥ 18
• 2. With post-COVID syndrome
• 3. Has had a recent (within 7 days) negative SARS-CoV-2 test (an approved PCR or antigen test)
• 4. Able to provide signed informed consent (by the subject or his/her legally authorized representative)
• 5. Is willing and able to participate in all aspects of the study, including completion of subjective evaluations, attendance at scheduled clinic visits, and compliance with all protocol requirements as evidenced by providing a written informed consent

You may not qualify if…

• 1. Neurological disorders prior to COVID-19 diagnosis
• 2. With pre-existing terminal illness
• 3. With known immune disease
• 4. Is pregnant or breastfeeding
• 5. Is currently participating in another investigational study or has been taking any other investigational product within the last 4 weeks before screening
• 6. Has received any vaccination within 3 weeks prior to the first IP infusion
• 7. Judged by the investigator to be not suitable for study participation
• 8. Under the conditions that may increase risk of complications based on the medical judgment of the investigator and the parameters

Where it is running

• Myrak Research Center — Miami Lakes, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.